Messenger RNA vaccines against SARS-CoV-2

被引：38

作者：

Topol, Eric J. ^{[1
]}

机构：

[1] Scripps Res, La Jolla, CA 92037 USA

来源：

CELL | 2021年 / 184卷 / 06期

关键词：

D O I：

10.1016/j.cell.2020.12.039

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF. © 2020 Elsevier Inc.; The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF. © 2020 Elsevier Inc.

引用

页码：1401 / 1401

页数：1

共 2 条

[1]

Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., Et al., An mRNA Vaccine against SARS-CoV-2 - Preliminary Report, N. Engl. J. Med., 383, pp. 1920-1931, (2020)

[2]

Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., Et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med., 383, pp. 2603-2615, (2020)

← 1 →